Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers

• ClinicalTrials.gov Identifier: NCT02244190
• Recruitment Status: Completed
• First Posted: September 19, 2014
• Last Update Posted: September 19, 2014
• Sponsor: Boehringer Ingelheim
• Information provided by (Responsible Party): Boehringer Ingelheim

Study Description

Brief Summary:

To establish the bioequivalence of the new tipranavir oral solution formulation with the current tipranavir oral solution formulation following single-dose administration. In each case, 500 mg tipranavir was coadministered with 200 mg ritonavir.

Condition or disease	Intervention/treatment	Phase
Healthy	Drug: Tipranavir; Drug: Ritonavir	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 32 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Bioequivalence of Two Different Oral Solutions of 500 mg of Tipranavir (New Formulation vs. Current Formulation) Administered in Combination With 200 mg of Ritonavir (Oral Solution) to Healthy Volunteers (an Open-label, Randomised, Single Dose, Two-way Crossover Study)
• Study Start Date: April 2008
• Actual Primary Completion Date: May 2008

Arms and Interventions

Arm	Intervention/treatment
Experimental: new Tipranavir + Ritonavir	Drug: Tipranavir; New oral solution (back up) formulation; Drug: Ritonavir; Other Name: Norvir®
Active Comparator: current Tipranavir + Ritonavir	Drug: Tipranavir; Other Name: Current oral solution formulation; Drug: Ritonavir; Other Name: Norvir®

Outcome Measures

Primary Outcome Measures :

1. AUC0-∞ (area under the concentration-time curve of drug in plasma over the time interval from 0 extrapolated to infinity) for tipranavir [ Time Frame: up to 72 hours after drug administration ]
2. Cmax (maximum measured concentration of drug in plasma) for tipranavir [ Time Frame: up to 72 hours after drug administration ]

Secondary Outcome Measures :

1. AUC0-∞ for ritonavir [ Time Frame: up to 72 hours after drug administration ]
2. Cmax for ritonavir [ Time Frame: up to 72 hours after drug administration ]
3. AUC0-tz (area under the concentration-time curve of drug in plasma over the time interval from 0 to the time of the last quantifiable data point) [ Time Frame: up to 72 hours after drug administration ]
4. tmax (time from dosing to the maximum concentration of drug in plasma) [ Time Frame: up to 72 hours after drug administration ]
5. λz (terminal rate constant of drug in plasma) [ Time Frame: up to 72 hours after drug administration ]
6. t1/2 (terminal half-life of drug in plasma) [ Time Frame: up to 72 hours after drug administration ]
7. MRTpo (mean residence time of drug in the body after oral administration) [ Time Frame: up to 72 hours after drug administration ]
8. CLpo/F (apparent clearance of drug after oral administration) [ Time Frame: up to 72 hours after drug administration ]
9. Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) [ Time Frame: up to 72 hours after drug administration ]
10. Number of patients with adverse events [ Time Frame: up to 43 days ]
11. Number of patients with clinically significant findings in vital signs [ Time Frame: up to 43 days ]
12. Number of patients with clinically significant findings in 12-lead electrocardiogram [ Time Frame: up to 43 days ]
13. Number of patients with clinically significant findings in laboratory tests [ Time Frame: up to 43 days ]
14. Assessment of tolerability by investigator on a 4-point scale [ Time Frame: Day 4 of each treatment period ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 55 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Healthy males and females according to the following criteria based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests
• Age ≥ 18 and ≤ 55 years
• BMI ≥ 18.5 and ≤ 29.9 kg/m2 (Body Mass Index) and body weight > 55 kg
• Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation

Exclusion Criteria:

• Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
• Any evidence of a clinically relevant concomitant disease
• Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
• Surgery of the gastrointestinal tract (except appendectomy)
• Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
• History of relevant orthostatic hypotension, fainting spells or blackouts.
• Chronic or relevant acute infections
• History of relevant allergy/hypersensitivity (including allergy to tipranavir or ritonavir or their excipients)
• Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration of the trial drug or during the trial
• Cytochrome P 450 (CYP3A4)-inhibiting drugs (e.g. itraconazole, ketoconazole, protease inhibitors, erythromycin, clarithromycin, telithromycin, nefazodone, cyclosporin, verapamil, amiodarone, diltiazem), CYP3A4 inducing drugs (e.g. St. John´s wort [Hypericum perforatum], rifampin, dexamethasone) or CYP3A4 substrates (e.g. triazolam, sertraline); further drugs which might reasonably influence the results of the trial (e.g. drugs which contain polyethylene glycol) or drugs that prolong the QT/corrected QT interval interval (based on the knowledge at the time of protocol preparation) within 14 days prior to first administration of the trial drug or during the trial
• Participation in another trial with an investigational drug within two months prior to administration of the trial drug or during the trial
• Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
• Inability to refrain from smoking within 24 hours before or after administration of the trial drug
• Alcohol abuse (more than 60 g/day)
• Drug abuse
• Blood donation (more than 100 mL within four weeks prior to administration of the trial drug or during the trial)
• Excessive physical activities (within one week prior to administration of the trial drug or during the trial)
• Any laboratory value outside the reference range that is of clinical relevance
• Inability to comply with dietary regimen of trial site
• A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
• A history of additional risk factors for Torsades de Pointes (TdP), e.g., heart failure, hypokalaemia, family history of Long QT Syndrome
• Known hypersensitivity to antiretroviral drugs (marketed or experimental use as part of clinical research studies)
• Personal or family history of coagulation or bleeding disorders or bleeding tendencies
• Intake of vitamin E within 14 days prior to the first drug administration of this trial or during the trial
• Transaminase values (ALT /AST) greater than the upper limit of the normal laboratory reference range during screening

For female subjects:

• Pregnancy or positive pregnancy test, or planning to become pregnant during the study or within 1 month of study completion
• No adequate contraception during the study and until 1 month of study completion, i.e. not any of the following: implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence (for at least 1 month prior to enrolment), vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or surgical sterilisation (incl. hysterectomy). Females who do not have a vasectomised partner, are not sexually abstinent or surgically sterile will be asked to additionally use barrier contraception methods (e.g. condom, diaphragm with spermicide).
• Lactation period

Contacts and Locations

No Contacts or Locations Provided

More Information

Additional Information:

Related Info 

• Responsible Party: Boehringer Ingelheim
• ClinicalTrials.gov Identifier: NCT02244190
• Other Study ID Numbers: 1182.124
• First Posted: September 19, 2014
• Last Update Posted: September 19, 2014
• Last Verified: September 2014

Additional relevant MeSH terms:

Ritonavir; Tipranavir; HIV Protease Inhibitors; Viral Protease Inhibitors; Protease Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Anti-HIV Agents; Anti-Retroviral Agents; Antiviral Agents; Anti-Infective Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors